Cargando…
Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study
In a previous 15-day, Phase II study of patients with de novo or persistent/recurrent Cushing’s disease (core study), treatment with pasireotide 600 μg sc bid reduced urinary free cortisol (UFC) levels in 76 % of patients and normalized UFC in 17 %. The objective of this study was to evaluate the ef...
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085509/ https://www.ncbi.nlm.nih.gov/pubmed/23943009 http://dx.doi.org/10.1007/s11102-013-0503-3 |